ADGM vs BEAT vs CRMD vs ATRC vs NVCR

For growth investors, CorMedix Inc.

(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CorMedix Inc.

is actually cheaper at 14. 2x.

Over the past 5 years, CorMedix Inc.

(CRMD) delivered a total return of -6. 9%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATRC returned +84. 4% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.

(ADGM) is the lower-risk stock at 0. 87β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 147% more volatile than ADGM relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorMedix Inc.

(CRMD) is pulling ahead at 617. 0% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Over a 3-year CAGR, CRMD leads at 1583% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CorMedix Inc.

(CRMD) is the more profitable company, earning 52. 3% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRMD leads at 48. 2% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — CRMD leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CorMedix Inc.

(CRMD) trades at 14. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 414. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AtriCure, Inc.

(ATRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95)). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATRC: +84. 4%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADGM is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; CRMD is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.